Table 2.
Characteristics of Patients Included in the Plasma Studies.
| Patient Characteristics | Sunitinib (N = 44) | |
|---|---|---|
| Age | 57 (Median) | 41-76 (Range) |
| Gender | Number | Percentage |
| M | 31 | 70.5 |
| F | 13 | 29.5 |
| Previous nephrectomy⁎ | Number | Percentage |
| Y | 39 | 88.6 |
| N | 5 | 11.4 |
| Antiangiogenic drug | Number | Percentage |
| Sunitinib | 42 | 95.5 |
| Sorafenib | 1 | 2.3 |
| Pazopanib | 1 | 2.3 |
| Prior line(s) of treatment | Number | Percentage |
| 1 | 12 | 27.3 |
| 2 | 16 | 36.4 |
| 3 | 11 | 25.0 |
| 4 | 4 | 9.1 |
| 5 | 0 | 0 |
| 6 | 1 | 2.3 |
| Prior treatment | Number | Percentage |
| IL-2 | 20 | 45.5 |
| Avastin | 13 | 29.5 |
| Sorafenib | 12 | 27.3 |
| Pazopanib | 2 | 4.5 |
| Axitinib | 3 | 6.8 |
| mTOR inhibitor** | 2 | 4.5 |
| Clinical trial | 9 | 20.5 |
| Other | 4 | 9.1 |
⁎
Of the 39 patients who had prior Nx, 24 had cytoreductive nephrectomy. All patients were treated with VEGFR TKI for metastatic disease and not in the adjuvant or neoadjuvant setting.
** Mammalian target of rapamycin.